BioSpace News Archive

Bristol Myers Squibb to Take Part in the Cowen Virtual 41 st Annual Health Care Conference

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Cowen 41 st Annual Health Care Conference.

ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particularly in elderly populations. Phase 1 single ascending dose and multiple ascending dose studies have been completed in healthy volunteers including elderly subjects more than 65 years of age.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March: H.C. Wainwright Global Life Sciences Conference

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that John Beaver , President and Chief Executive Officer, will be providing an overview of the Company, as well as recent progress and achievements at the H.C. Wainwright Global Life Sciences Investor Conference

DaVita Inc. announced that it has commenced a private add-on offering of $750 million aggregate principal amount of its 4.625% senior notes due June 1, 2030, subject to market and other conditions.

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Raymond James 42 nd Annual Institutional Investors Conference on Wednesday, March 3, 2021 at 12:30 PM ET.

A merger and the launch of a $10 million dollar respiratory campaign, part of the McGill University Health Centre Foundation’s larger Dream Big campaign, will ensure the Montreal Chest Institute will continue as a world leader in respiratory care

Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, and the University of Utah , one of the top research institutions in the United States, today announced a partnership to improve kidney health and reduce the risk of kidney failure for large scale populations in the earliest stages of kidney disease.

Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives is pleased to announce it has commenced the application process to dual list its stock on the Frankfurt Stock Exhange.